Dr. Reddy's Laboratories is projected to report Q3 2026 revenue of $1.02 billion and an EPS of $0.16, while the stock currently trades at $17.42, roughly 14% below the average analyst price target of $19.85.
Investors are laser-focused on North America Generics revenue, particularly the ongoing sales trajectory and volume market share of the high-margin generic Revlimid.
Recent performance has been bolstered by strong momentum in the U.S. market and steady expansion across emerging markets, though base business price erosion remains a persistent headwind. Management commentary regarding the biosimilar pipeline and progress on GLP-1 generic development will be essential for assessing the company’s long-term growth ceiling.